Ultragenyx Pharmaceutical Analyst Ratings: Recent Assessments and Insights

Analysts' ratings on Ultragenyx Pharmaceutical have shifted, with 8 analysts sharing their insights over the past 3 months. The table below summarizes recent ratings, showing a mix of bullish and bearish sentiments. Analysts' 12-month price targets average $66.62, with a high of $105.00 and a low of $34.00. Recent ratings include Cantor Fitzgerald lowering its rating to Overweight with a price target of $105.00, and Wedbush lowering its rating to Neutral with a price target of $34.00.

Analysts' ratings on Ultragenyx Pharmaceutical (NASDAQ:RARE) have shifted over the past three months, with eight analysts providing insights. The table below summarizes recent ratings, showing a mix of bullish and bearish sentiments. Analysts' 12-month price targets average $66.62, with a high of $105.00 and a low of $34.00. Recent ratings include Cantor Fitzgerald lowering its rating to Overweight with a price target of $105.00, and Wedbush lowering its rating to Neutral with a price target of $34.00.

Cantor Fitzgerald, one of the leading research firms, reduced its price target for Ultragenyx Pharmaceutical from $112.00 to $105.00 while maintaining an "overweight" rating, suggesting a potential upside of 292.01% from the current price [1]. Wells Fargo, another major firm, significantly downgraded its target to $65.00 while setting an "overweight" rating. Guggenheim and HC Wainwright, on the other hand, have positive ratings with targets ranging from $64.00 to $80.00 [1].

Ultragenyx Pharmaceutical is expected to report a 9.9% increase in quarterly revenue for the period ending June 30, 2025, according to the mean estimate from 16 analysts [2]. However, the company is expected to post a loss of $1.30 per share, with analysts' earnings estimates remaining unchanged in the last three months [2].

The stock has seen mixed performance, trading down $2.14 during midday trading on Wednesday, reaching $26.79. The stock's 52-week low is $25.81, and the 52-week high is $60.37. Institutional investors own 97.67% of the company's stock, with several major investors increasing their stakes in the last quarter [1].

Overall, the mixed ratings and price targets from analysts indicate a range of expectations for Ultragenyx Pharmaceutical. Investors should carefully consider these insights and the company's recent earnings data when making investment decisions.

References:
[1] https://www.marketbeat.com/instant-alerts/ultragenyx-pharmaceutical-nasdaqrare-given-new-10500-price-target-at-cantor-fitzgerald-2025-08-06/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TT3A2:0-ultragenyx-pharmaceutical-inc-expected-to-post-a-loss-of-1-30-a-share-earnings-preview/